Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 10/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MMP13 | P45452 | 2/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.43 |
| ▸ | PHGDH | O43175 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6700620 | 0.92 | MMP13 (0.44) | PTGER4ALDH1A1MMP13EPHX2 | |
| SCHEMBL6817791 | 0.91 | KDM4E (0.43) | PTGER4ALDH1A1MMP13NR1H4EPHX2 | |
| SCHEMBL6817793 | 0.83 | SMN1; SMN2 (0.42) | ALDH1A1TP53SMN1; SMN2 | |
| SCHEMBL6702239 | 0.80 | MMP13 (0.41) | PTGER4ALDH1A1MMP13HPGDSMN1; SMN2 | |
| SCHEMBL6700597 | 0.79 | KDM4E (0.50) | PTGER4ALDH1A1MMP13NR1H4EPHX2 | |
| SCHEMBL6704724 | 0.75 | TP53 (0.50) | PTGER4ALDH1A1TP53SMN1; SMN2 | |
| SCHEMBL6702617 | 0.74 | MMP13 (0.41) | PTGER4ALDH1A1MMP13 | |
| SCHEMBL6704242 | 0.73 | PTGER4 (0.36) | PTGER4ALDH1A1MMP13 | |
| SCHEMBL6700586 | 0.73 | PTGER4 (0.46) | PTGER4ALDH1A1MMP13NR1H4EPHX2 | |
| SCHEMBL6699803 | 0.73 | PTGER4 (0.48) | PTGER4ALDH1A1MMP13NR1H4EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | WILSON MICHAEL WILLIAM (US) | 2004-02-26 | — | — | US | disclosed |
| WO-2004014916-A1 | PYRIMIDINE FUSED BICYCLIC METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038994-A1 | Pyrimidine fused bicyclic metalloproteinase inhibitors | MMP9, MMP1, MMP2 | PTGER4 1609/4885ALDH1A1 221/4885MMP13 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.